Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource oncology regimen Prior Auth Policy Upda…
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Oncology treatment regimen review via Eviti Connect

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and review requirements for oncology treatment regimens submitted through the NantHealth Eviti Connect portal and applies to oncology drug regimens covered under the pharmacy/oncology benefit for CareSource members in Arkansas PASSE.

    Policy Summary
    PayerCareSource
    PolicyOncology treatment regimen review via Eviti Connect
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewOct 3, 2024
    Next Review DateN/A
    Key ActionSubmit all oncology treatment regimens to Eviti Connect for review to obtain an Eviti-issued regimen code and authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moinitial authorization duration
    12 more-authorization duration
    Eviti Connectsubmission platform

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oncologistprescriber requirement

    Coverage Criteria for Oncology Regimens

    inv-01: Initial Therapy

    Covered when ALL of the following are met for initial authorization:

    Initial Therapy: 1) The oncology drug(s) are prescribed by an oncologist or hematologist; 2) The regimen has sufficient supporting evidence as determined by one or more of: a) FDA-approved indication(s); b) NCCN evidence categories 1, 2a, or 2b; c) recommendations within the Eviti evidence-based medical library such as nationally recognized peer-reviewed medical journal articles or professional society oncology treatment standards and guidelines; 3) The dose(s) do not exceed the FDA labeled maximum or what is supported by compendia or reference guidelines; 4) Medical records, applicable lab results, and/or test results (including genetic mutation testing when applicable) are provided to confirm the diagnosis and provide baseline information; 5) Chart notes document any and all previous treatments for the member's cancer; 6) The member has no contraindications to the requested treatment; 7) If the request is for a non-preferred/non-formulary drug and a comparable preferred drug is available (e.g., biosimilar or a drug in the same mechanistic class with similar efficacy and safety), the member has tried the comparable preferred regimen first and shown lack of response, unless not tolerated or contraindicated; 8) The request is not for experimental or investigational purposes and is not for use in a clinical trial.authorization up to 6 months

    Regimen-level review includes supportive care medications and is performed via Eviti Connect.

    inv-02: Continuation Therapy

    Reauthorization covered when ALL of the following are met:

    Continuation Therapy: Chart notes document improvement or stabilization of disease based on clinical narrative, imaging, or current clinical biomarker/lab results.authorization up to an additional 12 months

    Scenarios not meeting these requirements may be considered on a case-by-case basis with timely supporting literature from nationally recognized peer-reviewed journals.

    Requests for treatment under this regimen review policy that are intended for experimental or investigational purposes or for participation in a clinical trial are excluded from authorization. This aligns with the requirement that initial authorizations must meet established evidence standards and explicitly states that uses classified as experimental/investigational or trial-related will not be approved under the regimen review process.

    Initial Authorization Requirements

    inv-10: Initial authorization

    Initial therapy requirements

    Initial authorization: 1) Prescribed by an oncologist or hematologist; 2) Evidence support via FDA approval, NCCN categories 1/2a/2b, or Eviti evidence library (peer-reviewed literature or professional society guidelines); 3) Doses do not exceed FDA labeled maximums or compendia-supported limits; 4) Provide medical records, applicable lab and/or test results (including genetic mutation testing when applicable) to confirm diagnosis and baseline; 5) Chart notes document prior cancer treatments; 6) No documented contraindications to the requested treatment; 7) For non-preferred agents, trial of a comparable preferred regimen (e.g., biosimilar or same mechanistic class) with lack of response documented unless not tolerated/contraindicated; 8) Not for experimental/investigational use or for a clinical trial.authorization up to 6 months

    Regimen-level review via Eviti Connect; Eviti-issued regimen codes and resulting authorization information are forwarded to the payer.

    Reauthorization / Continuation Requirements

    inv-11: Reauthorization

    Reauthorization requirements

    Reauthorization: Chart notes documenting improvement or stabilization of disease via clinical narrative, imaging, or biomarkers are required for additional authorization.authorization up to an additional 12 months

    Exceptions may be considered on a case-by-case basis if timely clinical literature from nationally recognized peer‑reviewed journals is submitted.

    Provider Submission and Documentation Requirements

    Prior Authorization

    Eviti Connect submission required

    All oncology treatment regimens must be submitted to Eviti Connect for review via the NantHealth Eviti Connect portal. Eviti-issued regimen codes and resulting authorization information will be forwarded to CareSource. Eviti Connect review covers the regimen in its entirety, including supportive care medications and drugs that might otherwise not require PA.

    • Eviti Connect submission required for all oncology regimens
    • Eviti-issued regimen codes communicated to CareSource
    Step Therapy

    Preferred regimen required prior to non-preferred

    If a comparable preferred regimen (including a biosimilar or another agent in the same mechanistic class with similar efficacy and safety) is available, the member must try the preferred regimen first and show a lack of response, intolerance, or contraindication before a non-preferred/non-formulary drug will be authorized. This step requirement applies to initial requests for non-preferred agents used within an oncology regimen.

    Step Therapy / Prior Preferred Regimen Requirements

    StepRequirementFailure criteria
    1Trial of a comparable preferred regimen (e.g., a biosimilar or a drug in the same mechanistic class with similar efficacy/safety) is required before authorization of a non-preferred/non-formulary drug unless the preferred regimen is not tolerated or is contraindicated.Lack of response to the preferred comparable regimen

    Site of Care Notes

    Note

    Eviti Connect manages regimen review and site‑of‑care labeling

    Oncology regimens are managed via Eviti Connect; benefit labeling designates Oncology Regimens = Medical (Arkansas PASSE) and the Eviti review issues an Eviti code to indicate the regimen met evidence‑based standards and that an authorization has been forwarded to CareSource (the Eviti code is not a guarantee of payment).

    Key Definitions

    Eviti code
    DefinitionAn identifier issued by Eviti Connect indicating the treatment plan met evidence-based standards and that the review process was completed; it does not guarantee payment.
    PurposeIndicates the regimen-level review was completed and that an authorization was forwarded to CareSource.
    ScopeIssued when oncology treatment regimens (including supportive care medications) comply with evidence-based medicine and national standards of quality care.
    Not a payment guaranteeEviti code issuance does not guarantee payment — it documents review completion and forwarding of authorization information to the payer.
    Associated processGenerated through review via the NantHealth Eviti Connect portal connecting oncology offices with CareSource for real-time validation.

    Background

    Eviti Connect performs an evidence-based validation of oncology treatment plans at the regimen level, including supportive care medications. The review confirms that the proposed regimen meets one or more accepted evidence sources—FDA-approved indications, NCCN evidence categories 1/2a/2b, or recommendations in the Eviti evidence library (for example, nationally recognized peer-reviewed journals or professional society guidelines)—and that dosing and documentation requirements are met. An Eviti-issued regimen code indicates the review was completed and that authorization information has been forwarded to CareSource; however, the code does not guarantee payment.

    Policy Summary
    PayerCareSource
    PolicyOncology treatment regimen review via Eviti Connect
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewOct 3, 2024
    Next Review DateN/A
    Key ActionSubmit all oncology treatment regimens to Eviti Connect for review to obtain an Eviti-issued regimen code and authorization.
    SourceLink
    On This Page
    Coverage Criteria for Oncology RegimensInitial Authorization RequirementsReauthorization / Continuation RequirementsProvider Submission and Documentation RequirementsStep Therapy / Prior Preferred Regimen RequirementsSite of Care NotesKey DefinitionsBackground
    • Step therapy required prior to approval of non-preferred/non-formulary oncology drugs
    • Exceptions allowed for intolerance or contraindication documented in the chart
    Documentation Required

    Required documentation

    Provide medical records, applicable lab results, genetic testing results (when relevant), and chart notes documenting diagnosis, baseline information, and all prior cancer treatments. Dose must not exceed FDA-labeled maximums or limits supported by compendia/guidelines. Requests for initial authorization must include documentation that the prescribing clinician is an oncologist or hematologist.

    • Required: medical records, labs, genetic testing, and chart notes of prior treatments
    • Dose must be within FDA labeling or compendia-supported limits
    • Prescriber must be an oncologist or hematologist
    Denial Risk

    Potential triggers for denial

    Requests lacking adequate supporting evidence (FDA approval, NCCN category 1/2a/2b, or other Eviti-supported evidence), insufficient documentation, use outside accepted evidence-based categories, or regimen use for experimental purposes/clinical trial will be at high risk for denial. Non-preferred drug requests without documented trial and failure of a preferred alternative (or intolerance/contraindication) may be denied.

    • Potential denial triggers: insufficient clinical evidence or documentation
    • Use not supported by FDA/NCCN/Eviti evidence categories
    • Non-preferred requests without documented trial/failure of preferred regimen
    Billing Rule

    BIOSIMILAR — use preferred comparable drug when available

    When a biosimilar or other comparable preferred agent exists, the preferred product must be used in the regimen unless the member has documented intolerance or contraindication. Reviewers will determine whether a biosimilar or same-class alternative is sufficiently comparable to require use prior to authorizing a non-preferred agent.

    • Biosimilar or same-class preferred drugs must be used when available
    • Document intolerance or contraindication to consider non-preferred agent